TANGO THERAPEUTICS INC (TNGX) Stock Price, Forecast & Analysis
USA - NASDAQ:TNGX - US87583X1090 - Common Stock
TNGX Key Statistics, Chart & Performance
The current stock price of TNGX is 7.51 USD. In the past month the price increased by 8.68%. In the past year, price increased by 154.58%.
TNGX Latest News, Press Relases and Analysis
TNGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About TNGX
Company Profile
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Company Info
TANGO THERAPEUTICS INC
201 Brookline Avenue, Suite 901
Boston MASSACHUSETTS US
CEO: Aaron I. Davis
Employees: 155
Phone: 18573204900
TANGO THERAPEUTICS INC / TNGX FAQ
What does TANGO THERAPEUTICS INC do?
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
What is the current price of TNGX stock?
The current stock price of TNGX is 7.51 USD. The price decreased by -6.24% in the last trading session.
Does TNGX stock pay dividends?
TNGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TNGX stock?
TNGX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of TANGO THERAPEUTICS INC (TNGX)?
TANGO THERAPEUTICS INC (TNGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).
Is TANGO THERAPEUTICS INC (TNGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TNGX.
What is the expected growth for TNGX stock?
The Revenue of TANGO THERAPEUTICS INC (TNGX) is expected to grow by 8.57% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
TNGX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TNGX. When comparing the yearly performance of all stocks, TNGX is one of the better performing stocks in the market, outperforming 95.91% of all stocks.
TNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TNGX. TNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TNGX Financial Highlights
Over the last trailing twelve months TNGX reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 21.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.19% | ||
| ROE | -107.86% | ||
| Debt/Equity | 0 |
TNGX Forecast & Estimates
15 analysts have analysed TNGX and the average price target is 12.37 USD. This implies a price increase of 64.68% is expected in the next year compared to the current price of 7.51.
For the next year, analysts expect an EPS growth of 8.28% and a revenue growth 8.57% for TNGX